The Health, Aged Care and Sport Committee will hold a public hearing at Parliament House in Canberra as part of its inquiry into diabetes this Friday, 22 March 2024.
The Committee will hear from a variety of pharmaceutical companies and manufacturers, including Dexcom/AMSL Diabetes, Eli Lilly Australia, Medtronic and Insulet Australia, who provide life-saving diabetes medications and equipment. The Committee will also hear from Novo Nordisk, manufacturer of Ozempic.
The Chair of the Committee, Dr Mike Freelander MP, said: ‘Throughout the inquiry, the Committee has heard a lot of evidence about patients’ experiences and challenges accessing and using life-saving medication, devices and equipment to manage their diabetes. This public hearing will explore steps that the Australian Government can take to improve access to these management and treatment options.’
The Deputy Chair of the Committee, Mrs Melissa McIntosh MP, said: ‘The growing impact of diabetes in Australia, including the growing prevalence of the autoimmune disease type 1 diabetes, has been a core focus for this inquiry. At this hearing, we will also hear from Jane McDonald, a person living with type 1 diabetes, about her journey through diagnosis, treatment and management.’
Public hearing
Date: Friday, 22 March 2024
Time: 8.45am – 5.30pm AEDT (Canberra time)
Location: Committee Room 1R3, Parliament House, Canberra
A program for the public hearing is available on the inquiry website. A live audio stream of the hearings will also be available on the APH website.
Media inquiries
Dr Mike Freelander MP – Committee Chair
[email protected]
(02) 4620 0293
Mrs Melissa McIntosh MP – Committee Deputy Chair
[email protected]
(02) 4722 0600
For background information
Committee Secretariat
02 6277 4145
[email protected]